85%Confidence
0Views
FDASource
2026-03-15Date
Summary
Slate Run Pharmaceuticals recalls Eptifibatide Injection due to labeling error, a Class III issue indicating incorrect dosing instructions. While less severe, this could cause medication errors and requires corrective action to maintain compliance and patient safety.
Actionable: Verify all labeling for Slate Run's injectable products and implement quality checks to prevent similar misbranding incidents.
AI Confidence: 85%
Data Points
firmSlate Run Pharmaceuticals
classificationClass III
statusOngoing
distributionNationwide within the USA.
productEptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now